Total Payments
$1,698
2024 Payments
$325.56
Companies
14
Transactions
103
Medicare Patients
4,116
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$1,625 (95.7%)
Education$73.70 (4.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,625 | 97 | 95.7% |
| Education | $73.70 | 6 | 4.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $774.27 | 42 | $0 (2024) |
| Astellas Pharma US Inc | $249.31 | 17 | $0 (2021) |
| ViiV Healthcare Company | $200.96 | 16 | $0 (2019) |
| Merck Sharp & Dohme LLC | $178.61 | 11 | $0 (2023) |
| Shionogi Inc | $102.28 | 4 | $0 (2024) |
| The Medicines Company | $32.75 | 3 | $0 (2017) |
| ABBVIE INC. | $30.89 | 2 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $25.11 | 1 | $0 (2024) |
| Melinta Therapeutics, LLC | $23.17 | 2 | $0 (2022) |
| Insmed, Inc. | $20.79 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $325.56 | 14 | Gilead Sciences, Inc. ($221.10) |
| 2023 | $323.39 | 17 | Gilead Sciences, Inc. ($227.41) |
| 2022 | $240.73 | 15 | Gilead Sciences, Inc. ($194.61) |
| 2021 | $124.30 | 7 | Gilead Sciences, Inc. ($65.83) |
| 2019 | $65.84 | 5 | ViiV Healthcare Company ($39.30) |
| 2018 | $229.04 | 17 | Astellas Pharma US Inc ($80.66) |
| 2017 | $389.35 | 28 | Astellas Pharma US Inc ($143.31) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.49 | General |
| 10/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.04 | General |
| 08/05/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 07/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.04 | General |
| 07/16/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.91 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.26 | General |
| 05/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.02 | General |
| 04/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.26 | General |
| 03/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.14 | General |
| 02/14/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Education | In-kind items and services | $11.59 | General |
| Category: COVID-19 | ||||||
| 01/23/2024 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 01/04/2024 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/06/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/04/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: COVID-19 | ||||||
| 11/02/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: COVID-19 | ||||||
| 10/23/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: COVID-19 | ||||||
| 10/23/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Education | In-kind items and services | $10.53 | General |
| Category: COVID-19 | ||||||
| 09/26/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: COVID-19 | ||||||
| 08/28/2023 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $16.30 | General |
| Category: GI | ||||||
| 08/14/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.57 | General |
| 07/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.44 | General |
| 06/14/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.65 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 898 | 82,089 | $792,746 | $227,446 |
| 2022 | 11 | 872 | 47,878 | $575,348 | $181,301 |
| 2021 | 15 | 1,003 | 65,957 | $699,829 | $246,848 |
| 2020 | 15 | 1,343 | 125,856 | $1.0M | $353,617 |
Total Patients
4,116
Total Services
321,780
Medicare Billing
$1.0M
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 184 | 1,485 | $279,875 | $89,118 | 31.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 113 | 515 | $116,525 | $46,732 | 40.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 202 | 238 | $93,550 | $29,217 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 204 | $44,800 | $19,255 | 43.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 97 | 386 | $77,200 | $17,650 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 126 | $20,200 | $7,868 | 39.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 16 | 46 | $24,920 | $7,603 | 30.5% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 42 | 278 | $41,700 | $2,888 | 6.9% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 33 | 77,450 | $43,035 | $2,800 | 6.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 23 | 102 | $16,320 | $2,149 | 13.2% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 11 | 15 | $9,705 | $1,186 | 12.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 38 | 1,232 | $22,176 | $510.97 | 2.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 11 | 12 | $2,740 | $469.08 | 17.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 191 | 1,343 | $154,445 | $71,476 | 46.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 186 | 222 | $72,150 | $29,881 | 41.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 134 | 358 | $55,490 | $27,335 | 49.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 89 | 346 | $69,200 | $16,521 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 54 | 169 | $25,350 | $15,989 | 63.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 76 | 135 | $13,500 | $8,716 | 64.6% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2022 | 34 | 396 | $59,400 | $5,741 | 9.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 63 | $5,670 | $1,877 | 33.1% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 24 | 43,847 | $92,079 | $1,819 | 2.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 20 | 71 | $11,360 | $1,583 | 13.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 44 | 928 | $16,704 | $363.70 | 2.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 215 | 1,947 | $223,905 | $106,629 | 47.6% |
About Dr. Michael Miedler, MD
Dr. Michael Miedler, MD is a Infectious Disease healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1548261837.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Miedler, MD has received a total of $1,698 in payments from pharmaceutical and medical device companies, with $325.56 received in 2024. These payments were reported across 103 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($1,625).
As a Medicare-enrolled provider, Miedler has provided services to 4,116 Medicare beneficiaries, totaling 321,780 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Lexington, KY
- Active Since 08/09/2005
- Last Updated 03/04/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1548261837
Products in Payments
- Veklury (Drug) $125.35
- ZERBAXA (Drug) $107.51
- Fetroja (Drug) $102.28
- Cresemba (Drug) $98.87
- TRIUMEQ (Drug) $78.47
- CRESEMBA (Drug) $76.66
- JULUCA (Drug) $75.12
- DIFICID (Drug) $71.10
- VIBATIV (Drug) $36.45
- MINOCIN IV (Drug) $32.75
- DALVANCE (Drug) $30.89
- Mycamine (Drug) $30.48
- AMBISOME (Drug) $29.34
- DOVATO (Drug) $26.74
- Vabomere (Drug) $23.17
- Arikayce (Drug) $20.79
- TIVICAY (Drug) $20.63
- AVYCAZ (Drug) $17.50
- VOWST (Biological) $16.30
- PANZYGA (Biological) $14.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lexington
Dr. David Dougherty, M.d, M.D
Infectious Disease — Payments: $110,300
Infectious Disease $110,300
Daniel Rodrigue, Md, MD
Infectious Disease — Payments: $50,659
Infectious Disease $50,659
Charles Rose
Infectious Disease — Payments: $42,996
Infectious Disease $42,996
Dr. Marty Allen, M.d, M.D
Infectious Disease — Payments: $39,505
Infectious Disease $39,505
John Meek, Md, MD
Infectious Disease — Payments: $13,273
Infectious Disease $13,273
Mark Dougherty, Md, MD
Infectious Disease — Payments: $12,643
Infectious Disease $12,643